



BETA DRUGS LIMITED

BDL/PKL/SEC/2025
25th January, 2025

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/I, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

SYMBOL-BETA

Subject: Integrated Filing (Financial) for the quarter ended December 31, 2024

Dear Sir/Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31 2024, NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith Integrated Filing (Financial) for the quarter ended December 31, 2024.

Request you to kindly take above on record.

Thanking You
Your's faithfully
For Beta Drugs Ltd.

Rajni
Brar
Company Secretary

Digitally signed
by Rajni Brar
Date: 2025.01.25
11:29:08 +05'30'

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com

A. FINANCIAL RESULTS –Not applicable as the company is listed on SME platform.

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. –_Not applicable as the company is listed on SME platform.

Statement on deviation / variation in utilisation of funds raised	
Name of listed entity	
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issues / QIP / Others
Date of Raising Funds	
Amount Raised	
Report filed for Quarter ended	
Monitoring Agency	applicable / not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	Yes / No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	
Comments of the auditors, if any	
Objects for which funds have been raised and where there has been	

Beta Drugs Limited

Company Secretary
ACS - 24684

a deviation, in the following table				
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised
<p>Deviation or variation could mean:</p> <p>(a) Deviation in the objects or purposes for which the funds have been raised or</p> <p>(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or</p> <p>(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.</p> <p>Name of Signatory</p> <p>Designation</p>				

C. **FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES - Not Applicable as we don't have any default on loans and debt securities outstanding as on December 31, 2024.**

D. **FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half yearly filings i.e., 2nd and 4th quarter)- Not applicable as the company is listed on SME platform.**

E. **STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - Not Applicable.**

Beta Drugs Limited

 Company Secretary
 ACS - 24684